ES2378994T3 - Procedimientos para la preparación de derivados de isotiazol - Google Patents

Procedimientos para la preparación de derivados de isotiazol Download PDF

Info

Publication number
ES2378994T3
ES2378994T3 ES05778840T ES05778840T ES2378994T3 ES 2378994 T3 ES2378994 T3 ES 2378994T3 ES 05778840 T ES05778840 T ES 05778840T ES 05778840 T ES05778840 T ES 05778840T ES 2378994 T3 ES2378994 T3 ES 2378994T3
Authority
ES
Spain
Prior art keywords
aryl
benzyloxy
ureido
alkyl
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05778840T
Other languages
English (en)
Spanish (es)
Inventor
David B. Damon
Brian P. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
OSI Pharmaceuticals LLC
Original Assignee
Pfizer Inc
OSI Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc, OSI Pharmaceuticals LLC filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2378994T3 publication Critical patent/ES2378994T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES05778840T 2004-08-26 2005-08-02 Procedimientos para la preparación de derivados de isotiazol Expired - Lifetime ES2378994T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60454204P 2004-08-26 2004-08-26
US604542P 2004-08-26
PCT/US2005/027398 WO2006026034A2 (en) 2004-08-26 2005-08-02 Processes for the preparation of isothiazole derivatives

Publications (1)

Publication Number Publication Date
ES2378994T3 true ES2378994T3 (es) 2012-04-19

Family

ID=36000502

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05778840T Expired - Lifetime ES2378994T3 (es) 2004-08-26 2005-08-02 Procedimientos para la preparación de derivados de isotiazol

Country Status (21)

Country Link
US (2) US8884025B2 (enExample)
EP (1) EP1784183B1 (enExample)
JP (2) JP5100390B2 (enExample)
KR (1) KR100893977B1 (enExample)
CN (1) CN101043888B (enExample)
AR (1) AR050613A1 (enExample)
AT (1) ATE542533T1 (enExample)
AU (1) AU2005280451B2 (enExample)
BR (1) BRPI0514667A (enExample)
CA (1) CA2578023C (enExample)
DK (1) DK1784183T3 (enExample)
ES (1) ES2378994T3 (enExample)
IL (1) IL181063A0 (enExample)
MX (1) MX2007002246A (enExample)
NO (1) NO20071319L (enExample)
PL (1) PL1784183T3 (enExample)
PT (1) PT1784183E (enExample)
RU (1) RU2349588C2 (enExample)
TW (1) TWI361688B (enExample)
WO (1) WO2006026034A2 (enExample)
ZA (1) ZA200701016B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101043888B (zh) 2004-08-26 2010-08-11 辉瑞有限公司 制备异噻唑衍生物的方法
US8969583B2 (en) 2011-12-28 2015-03-03 Allergan, Inc. 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
CN103833665B (zh) * 2014-02-24 2015-09-23 杰达维（上海）医药科技发展有限公司 一种新的合成异噻唑的方法
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9403803B2 (en) 2014-10-08 2016-08-02 Allergan, Inc. Indole-3-carboxamides as kinase inhibitors
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
US9371314B2 (en) 2014-10-09 2016-06-21 Allergan, Inc. Pyridyl benzothiophenes as kinase inhibitors
KR20250121146A (ko) * 2022-12-28 2025-08-11 비양 테라퓨틱스 컴퍼니 리미티드 단백질 티로신 키나제 억제제 및 이의 의약적 용도
WO2026002126A1 (zh) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂及其眼用制剂
WO2026002137A1 (zh) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂游离碱的晶型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2408234A1 (de) * 1974-02-21 1975-09-04 Celamerck Gmbh & Co Kg Isothiazolylharnstoffe
US4059433A (en) * 1976-06-18 1977-11-22 Fmc Corporation 3-Alkoxyisothiazole derivatives as herbicides
IL72093A0 (en) * 1983-06-20 1984-10-31 Lilly Co Eli N'-substituted(3-alkyl-5-isothiazolyl)urea derivatives
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
CA2493701A1 (en) * 2002-07-25 2004-02-05 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
US20060035954A1 (en) * 2004-08-11 2006-02-16 Sharma Padam N Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
CN101043888B (zh) 2004-08-26 2010-08-11 辉瑞有限公司 制备异噻唑衍生物的方法

Also Published As

Publication number Publication date
JP2012153705A (ja) 2012-08-16
CN101043888A (zh) 2007-09-26
BRPI0514667A (pt) 2008-06-17
MX2007002246A (es) 2007-04-20
ATE542533T1 (de) 2012-02-15
CA2578023C (en) 2012-05-15
KR100893977B1 (ko) 2009-04-20
EP1784183A4 (en) 2009-12-09
KR20070070158A (ko) 2007-07-03
JP2008510841A (ja) 2008-04-10
US20090023924A1 (en) 2009-01-22
WO2006026034A2 (en) 2006-03-09
HK1111359A1 (en) 2008-08-08
US8884025B2 (en) 2014-11-11
JP5498524B2 (ja) 2014-05-21
EP1784183B1 (en) 2012-01-25
AU2005280451A1 (en) 2006-03-09
RU2007106847A (ru) 2008-08-27
NO20071319L (no) 2007-05-29
JP5100390B2 (ja) 2012-12-19
AR050613A1 (es) 2006-11-08
DK1784183T3 (da) 2012-04-02
PT1784183E (pt) 2012-03-09
PL1784183T3 (pl) 2012-07-31
AU2005280451B2 (en) 2009-02-05
US9371298B2 (en) 2016-06-21
TW200621241A (en) 2006-07-01
CN101043888B (zh) 2010-08-11
IL181063A0 (en) 2007-07-04
TWI361688B (en) 2012-04-11
WO2006026034A3 (en) 2006-06-29
ZA200701016B (en) 2008-05-28
EP1784183A2 (en) 2007-05-16
RU2349588C2 (ru) 2009-03-20
CA2578023A1 (en) 2006-03-09
US20150065726A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
US9371298B2 (en) Processes for the preparation of isothiazole derivatives
AU2018306606B2 (en) Compounds and methods for the targeted degradation of Androgen Receptor
ES2610611T3 (es) Derivado de 2-acilaminotiazol o sal del mismo
ES2442369T3 (es) Derivados de quinolina y quinoxalina como inhibidores de cinasa
US7456164B2 (en) 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
ES2393245T3 (es) Compuesto de azol
ES2321186T3 (es) Dioxidos de tiadiazol y monoxidos de tiadiazol como ligandos de los receptores de quimioquinas cxc y cc.
ES2748402T3 (es) Derivado de 2-acilaminotiazol y sal del mismo
ES2346665T3 (es) Derivados de fenol y tiofenol 3- o 4-monosustituidos utiles como ligandos de h3.
ES2882279T3 (es) Composiciones farmacéuticas que comprenden donadores de nitroxilo
BR112015004192B1 (pt) sulfamoíl-arilamidas, composição farmacêutica que os compreende e uso das mesmas no tratamento da hepatite b
BR122016025225A2 (pt) Compostos 2-cefem substituídos e composição farmacêutica compreendendo ditos compostos
JP6858745B2 (ja) 細胞毒性ベンゾジアゼピン誘導体の調製方法
SA99200217B1 (ar) مشتقات ايزوثيازول isothiazole مفيدة كعوامل مضادة للسرطان anticancer
ES2206412T3 (es) Derivados de 8,8a-dihidro-indeno(1,2-d)tiazol que en posicion 2 portan un sustituyente con una estructura sulfonamida o sulfona, procedimiento para su preparacion y su uso como medicamentos.
WO2016148145A1 (ja) ピラゾロ［１，５－ａ］ピリミジン化合物
CN112165940A (zh) Ox2r化合物
JP2020510063A (ja) Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体
PH12015502671B1 (en) Heterocyclic amide compound
ES2375094T3 (es) Antagonistas del receptor de urotensina ii.
ES2641258T3 (es) Compuesto heterocíclico bicíclico
TW209216B (enExample)
AU2020296050A1 (en) Isoquinolinone derivatives serving as ROCK protein kinase inhibitors and use thereof
CN106279138B (zh) 芳杂环类衍生物及其在药物中的应用
ES2861050T3 (es) Procedimiento de producción de derivado de tiazol